DIRS.INFO The most relevant business & tech news

Cameroon will be the first country to routinely give children a new malaria vaccine as the shots are rolled out in Africa. Gavi said it is working with 20 other African countries to help them get the vaccine and that those countries will hopefully immunize more than 6 million children through 2025. Political Cartoons View All 253 ImagesCameroon will use the first of two recently approved malaria vaccines, known as Mosquirix. That vaccine is cheaper, requires three doses and India’s Serum Institute said they could make up to 200 million doses a year. Neither of the malaria vaccines stop transmission, so other tools like bed nets and insecticidal spraying will still be critical.

Persons: Aurelia Nguyen, Gavi, Gavi's Nguyen Organizations: World Health Organization, GlaxoSmithKline, GSK, Oxford University, WHO, Serum Institute, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: Cameroon, Africa, Central Africa, Oxford

A nurse fills a syringe with malaria vaccine before administering it to an infant at the Lumumba Sub-County hospital in Kisumu, Kenya, July 1, 2022. REUTERS/Baz Ratner/File photo Acquire Licensing RightsGENEVA, Oct 2 (Reuters) - The World Health Organization (WHO) recommended on Monday the use of a second malaria vaccine to curb the life-threatening disease spread to humans by some mosquitoes. recommended the broad use of the world's first malaria vaccine called RTS,S," WHO chief Tedros Adhanom Ghebreyesus told a briefing in Geneva. "Today, it gives me great pleasure to announce that WHO is recommending a second vaccine called R21/Matrix-M to prevent malaria in children at risk of the disease." "GSK has always recognised the need for a second malaria vaccine, but it is increasingly evident that RTS,S, the first ever malaria vaccine and the first ever vaccine against a human parasite, set a strong benchmark," GSK said in a statement.

Persons: Baz Ratner, Tedros Adhanom Ghebreyesus, Tedros, Poonawalla, Takeda, Hanna Nohynek, Gabrielle Tétrault, Farber, Leroy Leo, Gareth Jones, Mark Potter Organizations: Lumumba, REUTERS, Rights, World Health Organization, WHO, Britain's University of Oxford, UNICEF, Serum Institute of India, Reuters, GSK plc, United Nations, GSK, Takeda Pharmaceuticals, Thomson Locations: Kisumu, Kenya, Geneva, Ghana, Malawi, Bengaluru

LONDON (AP) — The World Health Organization authorized a second malaria vaccine on Monday, a decision that could offer countries a cheaper and a more readily available option than the world's first shot against the parasitic disease. “As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Alister Craig, an emeritus professor at the Liverpool School of Tropical Medicine, said he would recommend countries trying to get the GSK vaccine switch to the Oxford vaccine instead. Neither of the malaria vaccines stop transmission so immunization campaigns alone won’t be enough to stop epidemics. In a separate decision, WHO's expert group also authorized the dengue vaccine made by Takeda, which was previously approved by the European Union drug regulator.

Persons: Tedros Adhanom Ghebreyesus, ” Tedros, Tedros, it’s, ”, John Johnson, ” Johnson, Melinda Gates, Alister Craig, Craig, Takeda, Jamey Keaten Organizations: World Health Organization, WHO, Oxford University, Serum Institute of India, Research, Oxford, GSK, Melinda Gates Foundation, Serum, Liverpool School, Tropical, European Union, Associated Press, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: Ghana, Burkina Faso, Africa, Oxford, Bangladesh, Geneva

Oxford scientist Adrian Hill said Ghana's drug regulator has approved the vaccine domestically for the age group at highest risk of death from malaria - children aged 5 months to 36 months. Oxford has a deal with Serum Institute of India to produce up to 200 million doses of the vaccine - known as R21 - annually. "This shows how close the world is to having a second approved vaccine to fight malaria," he said. MEETING THE NEEDThe first malaria vaccine, Mosquirix from British drugmaker GSK (GSK.L), was endorsed by the WHO last year after decades of work. Since it began in 2019, 1.2 million children across the three countries have received at least one dose of the Mosquirix vaccine.

☆ BioNTech starts human trial to test malaria vaccine
▼ + stars: | 2022-12-23 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/IllustrationBERLIN, Dec 23 (Reuters) - BioNTech (22UAy.DE) on Friday initiated an early-stage study to evaluate its experimental malaria vaccine in humans, the German drugmaker said. The Phase 1 trial is expected to enrol 60 volunteers in the United States with no history of malaria to assess the vaccine candidate at three-dose levels. Known as BNT165b1, it is the first vaccine candidate from BioNTech's malaria project, which will also establish vaccine production in Africa. Another keenly-watched effort is a malaria vaccine from Oxford University. BioNTech's malaria vaccine effort is based on its mRNA technology, which was employed during the pandemic to quickly develop COVID-19 vaccines, by prompting the human body to make a protein that is part of the pathogen, triggering an immune response.

☆ Новая вакцина от малярии оказалась рекордно эффективной на 77%
▼ + stars: | 2021-04-24 | by ( Mld Media Srl | ) noi.md time to read: +2 min

Испытание вакцины против малярии, проведенной Оксфордским университетом, показало, что она эффективна на 77% — значительно лучше, чем существующие вакцины для предотвращения одной из самых смертоносных болезней в мире. Эта вакцина, известная как R21, является первой вакциной, которая может превзойти поставленную Всемирной организацией здравоохранения цель по созданию доступной вакцины с эффективностью не менее 75% к 2030 году. Mosquirix, первая вакцина против малярии, которая первоначально была внедрена в 2015 году, потребовала от GSK больше, чем 30 лет на разработку и около 39% эффективности за четыре года. В фазе 2b — средней стадии — испытания R21 у участников группы с более высокими дозами на 77% меньше вероятность развития малярии в течение 12 месяцев наблюдения, чем у тех, кто получил прививку от бешенства в качестве контроля. В ходе исследования были сделаны прививки 450 детям в возрасте от 5 до 17 месяцев в Буркина-Фасо.

Persons: Mosquirix, Novavax, Адриан Хилл, Дженнер Organizations: GSK, AstraZeneca Covid, Оксфордский университет, Всемирная организация здравоохранения, Оксфордский институт Locations: Oxford, Наноро, БуркинаФасо, Африка

Search resuls for: "Mosquirix"

6 mentions found